WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H326956
CAS#: 109872-41-5 (HCl)
Description: Renzapride, also known as ATL-1251; AZM-112; BRL-24924, is a 5-HT3 antagonist and 5-HT4 agonist potentially for the treatment of irritable bowel syndrome (IBS). Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT4 full agonist and 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors, though it is unlikely that these properties contribute to its therapeutic effects.
Hodoodo Cat#: H326956
Name: Renzapride hydrochloride
CAS#: 109872-41-5 (HCl)
Chemical Formula: C16H23Cl2N3O2
Exact Mass: 0.00
Molecular Weight: 360.279
Elemental Analysis: C, 53.34; H, 6.44; Cl, 19.68; N, 11.66; O, 8.88
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 112727-80-7 (free base) 109872-41-5 (HCl)
Synonym: Renzapride hydrochloride; Renzapride HCl; ATL-1251; AZM-112; BRL-24924; ATL1251; AZM112; BRL24924.
IUPAC/Chemical Name: 4-amino-N-((1R,4S,5R)-1-azabicyclo[3.3.1]nonan-4-yl)-5-chloro-2-methoxybenzamide hydrochloride
InChi Key: WYONTPMGUQWRKN-LOSLGVLSSA-N
InChi Code: InChI=1S/C16H22ClN3O2.ClH/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20;/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21);1H/t10-,14+;/m1./s1
SMILES Code: O=C(N[C@H]1CC[N@]2CCC[C@]1([H])C2)C3=CC(Cl)=C(N)C=C3OC.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# CAS#112727-80-7 (Renzapride) CAS#109872-41-5 (Renzapride hydrochloride)
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 360.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Mozaffari S, Nikfar S, Abdollahi M. Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients. Arch Med Sci. 2014 Feb 24;10(1):10-8. doi: 10.5114/aoms.2014.40729. Epub 2014 Feb 23. Review. PubMed PMID: 24701208; PubMed Central PMCID: PMC3953973.
2: Ford AC. Renzapride in IBS: is efficacy in the eye of the beholder? Aliment Pharmacol Ther. 2010 Jul;32(1):113-4; author reply 114-5. doi: 10.1111/j.1365-2036.2010.04275.x. PubMed PMID: 20597877.
3: Lembo AJ, Cremonini F, Meyers N, Hickling R. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study. Aliment Pharmacol Ther. 2010 May;31(9):979-90. doi: 10.1111/j.1365-2036.2010.04265.x. Epub 2010 Feb 16. PubMed PMID: 20163375.
4: Scarpellini E, Tack J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs. 2008 Nov;17(11):1663-70. doi: 10.1517/13543784.17.11.1663 . Review. PubMed PMID: 18922103.
5: Spiller RC, Meyers NL, Hickling RI. Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial. Dig Dis Sci. 2008 Dec;53(12):3191-200. doi: 10.1007/s10620-008-0295-x. Epub 2008 May 10. PubMed PMID: 18465239.
6: George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther. 2008 May;27(9):830-7. doi: 10.1111/j.1365-2036.2008.03649.x. Epub 2008 Feb 14. PubMed PMID: 18284648.
7: Meyers NL, Hickling RI. Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63. PubMed PMID: 18095752.
8: Meyers NL, Hickling RI. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome. J Int Med Res. 2007 Nov-Dec;35(6):848-66. PubMed PMID: 18034998.
9: Tack J, Middleton SJ, Horne MC, Piessevaux H, Bloor JS, Meyers NL, Palmer RM. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1655-65. PubMed PMID: 16696817.
10: Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D, Thomforde G, Baxter K, Zinsmeister AR. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004 Oct;2(10):895-904. PubMed PMID: 15476153.
11: Song CW, Lee KY, Kim CD, Chang TM, Chey WY. Effect of cisapride and renzapride on gastrointestinal motility and plasma motilin concentration in dogs. J Pharmacol Exp Ther. 1997 Jun;281(3):1312-6. PubMed PMID: 9190867.
12: Kilbinger H, Gebauer A, Haas J, Ladinsky H, Rizzi CA. Benzimidazolones and renzapride facilitate acetylcholine release from guinea-pig myenteric plexus via 5-HT4 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1995 Mar;351(3):229-36. PubMed PMID: 7609775.
13: Hansen MB, Thørboll JE, Beubler E, Skadhauge E. Effect of indomethacin, renzapride, methysergide, ketanserin, granisetron and citalopram on serotonin-induced fluid accumulation in pig jejunum. Physiol Res. 1994;43(2):83-93. PubMed PMID: 7918343.
14: Gullikson GW, Virina MA, Loeffler R, Erwin WD. Alpha 2-adrenergic model of gastroparesis: validation with renzapride, a stimulator of motility. Am J Physiol. 1991 Sep;261(3 Pt 1):G426-32. PubMed PMID: 1679600.
15: Mackie AD, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther. 1991 Apr;5(2):135-42. PubMed PMID: 1888816.
16: Craig DA, Clarke DE. Peristalsis evoked by 5-HT and renzapride: evidence for putative 5-HT4 receptor activation. Br J Pharmacol. 1991 Mar;102(3):563-4. PubMed PMID: 1364818; PubMed Central PMCID: PMC1917936.
17: Staniforth DH, Pennick M. Human pharmacology of renzapride: a new gastrokinetic benzamide without dopamine antagonist properties. Eur J Clin Pharmacol. 1990;38(2):161-4. PubMed PMID: 2338113.
